skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective

Review

(2263) Views  (531) Full article downloads

Authors: David J Brooks

Published Date March 2008 Volume 2008:4(1) Pages 39 - 47
DOI: http://dx.doi.org/10.2147/NDT.S1660

David J Brooks

Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK

Abstract: After 40 years of clinical experience, levodopa remains the gold standard treatment for Parkinson’s disease (PD) despite the recent emergence of a host of new therapies. Some physicians are cautious when prescribing levodopa because of its association with motor complications. Evidence now suggests that levodopa-associated complications are a result of deep troughs in delivery of levodopa to the brain caused by the short plasma half-life of conventional levodopa formulations (levodopa and a dopa decarboxylase inhibitor [DDCI]). Dosing strategies, such as dose increases and dose fractionation, may be effective in the short term. For the longer-term, levodopa/carbidopa/entacapone provides pharmacokinetically optimized levodopa therapy that significantly increases the plasma half-life and bioavailability of levodopa, providing more consistent plasma levodopa levels without deep troughs. Evidence from clinical trials in PD patients experiencing re-emergence of symptoms due to wearing-off has consistently shown that levodopa/DDCI and entacapone significantly increases ON-time and affords greater functionality, as measured by the Unified Parkinson’s Disease Rating Scale (UPDRS) with conventional levodopa. These trials have also shown that levodopa/DDCI and entacapone is generally well tolerated, with notable adverse events including worsening dyskinesia, nausea and diarrhea. Patients experiencing re-emergence of symptoms due to wearing-off may benefit from optimized levodopa therapy with levodopa/carbidopa/entacapone.

Keywords: levodopa, wearing-off, dyskinesia, entacapone, Stalevo








Readers of this article also read:

Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis
Erratum
Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
Corrigendum